Eli Lilly, Sanofi Breached Federal Law by Curbing Drug Discounts (2)

May 17, 2021, 4:57 PM; Updated: May 17, 2021, 9:51 PM

AstraZeneca, Eli Lilly & Co., and four other pharmaceutical companies violated a federal drug discount law by restricting price cuts geared for low-income patients, the Biden administration said Monday.

Separate letters issued by the Health Resources and Services Administration mark the latest turn in an ongoing fight over drug pricing under the federal 340B program, which requires drugmakers to give discounts to certain health centers. Sanofi and Novo Nordisk are also among the companies that HRSA said limited discounts for providers that dispense medications through off-site, “contract” pharmacies.

HRSA told the drugmakers that they “must immediately begin offering” their products ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.